Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
| ▸ | TEC | P42680 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24807726 | 0.91 | EGFR (0.47) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL30049652 | 0.91 | EGFR (0.47) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL24807729 | 0.90 | EGFR (0.47) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL30050657 | 0.89 | EGFR (0.53) | EGFRERBB2 | |
| SCHEMBL24807827 | 0.89 | EGFR (0.53) | EGFRERBB2 | |
| SCHEMBL31475819 | 0.86 | EGFR (0.43) | EGFRERBB2 | |
| SCHEMBL24807848 | 0.85 | EGFR (0.59) | EGFRERBB2 | |
| SCHEMBL24807740 | 0.85 | EGFR (0.48) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL24807843 | 0.84 | EGFR (0.51) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL24810301 | 0.84 | EGFR (0.51) | EGFRERBB2KCNH2RIPK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022269531-A1 | HER2 MUTATION INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041385-A1 | HER2 MUTATION INHIBITORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885KCNH2 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.